Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
Conditions
Keywords
ketorolac, GTPase, cancer, peritoneal, fallopian, ovarian
Brief summary
There is a move towards personalized medicine in cancer care, and significant effort is underway to evaluate new targeted therapeutics for the treatment of ovarian cancer. One way to identify potential new drug targets is by screening a drug library to determine whether drugs in the library target key kinase or enzymatic sites in cellular signaling pathways. Previous preclinical work and pilot studies demonstrated that ketorolac (a type of non-steroidal anti-inflammatory drug) inhibits GTPase activity in ovarian cancer cells retrieved from the post-operative peritoneal cavity. The purpose of this study is to confirm that this inhibitory effect is ketorolac driven and not a specific effect of the post-operative peritoneal compartment.
Detailed description
Drug repurposing, screening a library of FDA approved agents, can identify agents that are clinically available and for which pharmacology and pharmacokinetics are known and preclinical data can be generated rapidly without the subsequent need for GMP (good manufacturing practice) new drug production. Small GTPases, including members of the Rab, Ras and Rho families, are attractive targets for the development of cancer therapeutics based on their pivotal roles in protein trafficking, proliferation/survival and cytoskeletal organization, respectively. Ketorolac tromethamine is a non-steroidal anti-inflammatory drug that was identified in previous in-silico drug screens to be an inhibitor of GTPases. In a previous phase 0 clinical study, ketorolac was administered intravenously to ovarian cancer patients following optimal cytoreductive surgery. Ovarian cancer cells were obtained at the time of surgery, prior to ketorolac administration, and at various times after ketorolac dosing. Analysis of GTPase activity in these specimens showed a time-dependent inhibition of Rac1 and Cdc42 GTPase activity. The purpose of this study is to confirm that the effect is ketorolac driven and not a specific effect of the post-operative peritoneal compartment.
Interventions
DRUGKetorolac
Ketorolac tromethine 15 mg or 30 mg doses will be administered via intravenous (IV) push undiluted over 15 - 30 seconds Ketorolac will be dosed according to FDA approved recommendations. For planned three daily dose (IV) based on clinical scenario: * Patients \< 65 years of age: Daily dose of 30 mg for three doses. * Patients ≥ 65 years of age, renally impaired and/or less than 50 kg (110 lbs) of body weight: Daily dose of 15 mg for three doses Blood and peritoneal fluid will be drawn prior to each dose (time 0, 24, 48, 72 hr) as well as at 6 hr after the first dose
OTHERPlacebo
Equivalent volume of normal saline will be set in the syringe for each daily dose registered for the patient in a blinded fashion. The volume will be determined by the dose calculation as follows: For planned three daily dose (IV) based on clinical scenario: * Patients \< 65 years of age: Daily dose of 30 mg for three doses. * Patients ≥ 65 years of age, renally impaired and/or less than 50 kg (110 lbs) of body weight: Daily dose of 15 mg for three doses. Blood and peritoneal fluid will be drawn prior to each dose (time 0, 24, 48, 72 hr) as well as at 6 hr after the first dose
Sponsors
New Mexico Cancer Research Alliance
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must be suspected of having a diagnosis of ovarian, fallopian tube or primary peritoneal cancer with a planned cytoreductive surgery. * Borderline ovarian cancer with ascites is allowable. * ECOG/Zubrod/SWOG Performance Status \<2 (Karnofsky Performance Status \> 70%) * Female' age ≥18 years * Ability to provide informed consent * Baseline laboratory values (bone marrow, renal, hepatic): * Adequate bone marrow function: * Absolute neutrophil count \>1000/µL * Platelet count \>100'000/µL * Renal function: * Serum creatinine \< 1.5 x ULN * Hepatic function: * Bilirubin \<1.5x normal * Serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase \[AST\]) or serum glutamic-pyruvic transaminase (SGPT) (alanine aminotransferase \[ALT\]) levels ≤ 2 x ULN * No known bleeding disorders * No known sensitivity or allergy to NSAIDs * No active peptic ulcer disease * No active bleeding Secondary Eligibility * Histologic diagnosis of epithelial ovarian, fallopian tube or primary peritoneal cancer confirmed on frozen section diagnosis during debulking surgery * Attempted maximal cytoreductive surgery. Patients will still be eligible whether optimal or suboptimally debulked at the completion of the surgery. * No active bleeding in the post-operative period
Exclusion criteria
* Non-epithelial ovarian cancer or metastatic cancer from another site to the ovaries * Borderline ovarian cancer without ascites * Uncontrolled or unstable medical conditions * Off study use of ketorolac or other NSAIDs prior to study administration within the perioperative window (7 days before surgery and up to the time of planned study administration) * Active bleeding or high risk of bleeding * Active therapeutic anticoagulation * Known hypersensitivity to NSAIDs * Chronic or acute renal insufficiency as defined by a preoperative serum creatinine greater than 1.5 mg/dL or creatinine clearance of \< 40 ml/min * Any co-morbid condition that' in the view of the attending physician' renders the patient at high risk from ketorolac treatment complications
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Ketorolac inhibition of GTPase activity | Within 4 weeks of peritoneal cell collection | Ovarian cancer cells retrieved from the post-debulked peritoneal cavity after three intravenous dosings of ketorolac will be evaluated for GTPase activity using cell-based laboratory assays |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Intraperitoneal and serum pharmacokinetics of ketorolac | Within 4 weeks of peritoneal and blood specimen collection | Serum and intraperitoneal concentrations of ketorolac will be assessed over time using high performance liquid chromatography (HPLC) |
| Time to CA-125 normalization | Up to 6 months following first ketorolac treatment | CA-125 will be measured using a standard laboratory assay |
| Toxicity assessment | Up to 30 days following first ketorolac treatment | Subjective/objective evidence of developing drug toxicity will be evaluated according to NCI-CTC toxicity criteria (CTCAE version 3.0) |
Other
| Measure | Time frame | Description |
|---|---|---|
| Overall survival (Exploratory objective) | Up to 5 years following first ketorolac treatment | Time from treatment to death due to any cause |
| Progression free survival (Exploratory objective) | Up to 18 months following first ketorolac treatment | Time from treatment to progressive disease or death due to any cause |
Countries
United States
Outcome results
None listed